Stock CRDF CARDIFF ONCOLOGY, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Cardiff Oncology, Inc.

Equities

CRDF

US14147L1089

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
4.07 USD +2.01% Intraday chart for Cardiff Oncology, Inc. -6.44% +175.00%
Apr. 08 Cardiff Oncology Presents Novel Preclinical Data At Aacr Annual Meeting 2024 That Supports Ongoing First-Line Ras-Mutated Mcrc Clinical Study CI
Mar. 06 HC Wainwright Adjusts Price Target on Cardiff Oncology to $14 From $12, Keeps Buy Rating MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9.601 635.5 252.2 62.55 66.12 181.8 - -
Enterprise Value (EV) 1 9.601 635.5 252.2 62.55 66.12 181.8 181.8 181.8
P/E ratio -0.44 x -16.7 x -8.23 x -1.57 x -1.59 x -4.17 x -3.86 x -3.08 x
Yield - - - - - - - -
Capitalization / Revenue 39.2 x 1,736 x 703 x 162 x 135 x 750 x 2,727 x 2,727 x
EV / Revenue 39.2 x 1,736 x 703 x 162 x 135 x 750 x 2,727 x 2,727 x
EV / EBITDA - - - - - - - -
EV / FCF - -38.5 x -10.8 x -1.57 x -2.1 x -3.5 x -1.91 x -0.93 x
FCF Yield - -2.6% -9.22% -63.8% -47.6% -28.6% -52.2% -107%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 7,742 35,325 41,964 44,677 44,677 44,677 - -
Reference price 2 1.240 17.99 6.010 1.400 1.480 4.070 4.070 4.070
Announcement Date 2/27/20 2/25/21 2/24/22 3/2/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 0.245 0.366 0.359 0.386 0.488 0.2425 0.0667 0.0667
EBITDA - - - - - - - -
EBIT 1 -16.68 -19.09 -28.86 -39.9 -45.41 -47.25 -58.37 -77.94
Operating Margin -6,807.35% -5,214.86% -8,037.6% -10,337.31% -9,305.74% -19,485.77% -87,545.63% -116,904.15%
Earnings before Tax (EBT) 1 -16.41 -19.31 -28.29 -38.7 -41.44 -46.3 -57.9 -78.14
Net income 1 -16.71 -22.6 -28.32 -38.73 -41.46 -46.31 -57.91 -78.14
Net margin -6,819.18% -6,174.32% -7,887.19% -10,033.16% -8,496.93% -19,098.45% -86,857.66% -117,204.14%
EPS 2 -2.800 -1.080 -0.7300 -0.8900 -0.9300 -0.9750 -1.053 -1.323
Free Cash Flow 1 - -16.53 -23.24 -39.9 -31.47 -52 -95 -195
FCF margin - -4,515.65% -6,474.93% -10,337.31% -6,448.57% -21,443.3% -142,492.88% -292,485.38%
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 2/27/20 2/25/21 2/24/22 3/2/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 0.086 0.133 0.074 0.091 0.093 0.128 0.083 0.108 0.141 0.156 0.055 0.0588 0.0625 0.0662 0.025
EBITDA - - - - - - - - - - - - - - -
EBIT 1 -6.998 -9.526 -11.07 -10.44 -8.993 -9.392 -12.05 -12.21 -10.82 -10.33 -11.38 -11.5 -12.12 -12.25 -13.52
Operating Margin -8,137.21% -7,162.41% -14,964.86% -11,475.82% -9,669.89% -7,337.5% -14,520.48% -11,303.7% -7,673.76% -6,623.08% -20,689.09% -19,573.19% -19,397.2% -18,492.45% -54,100%
Earnings before Tax (EBT) 1 -6.913 -9.442 -10.99 -10.44 -8.571 -8.697 -11.22 -11.15 -9.731 -9.337 -11.14 -11.26 -11.89 -12.02 -13.42
Net income 1 -6.919 -9.448 -11 -10.45 -8.577 -8.721 -11.23 -11.16 -9.737 -9.343 -11.14 -11.26 -11.89 -12.02 -13.43
Net margin -8,045.35% -7,103.76% -14,863.51% -11,482.42% -9,222.58% -6,813.28% -13,528.92% -10,329.63% -6,905.67% -5,989.1% -20,251.36% -19,171.49% -19,026% -18,144.53% -53,724%
EPS 2 -0.1700 -0.2500 -0.2500 -0.2400 -0.2000 -0.2000 -0.2500 -0.2500 -0.2200 -0.2100 -0.2475 -0.2475 -0.2400 -0.2400 -0.2900
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/4/21 2/24/22 5/5/22 8/4/22 11/3/22 3/2/23 5/4/23 8/9/23 11/2/23 2/29/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 - -16.5 -23.2 -39.9 -31.5 -52 -95 -195
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - 0.21 - - - - - -
Capex / Sales - 57.89% - - - - - -
Announcement Date 2/27/20 2/25/21 2/24/22 3/2/23 2/29/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Cardiff Oncology, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.07 USD
Average target price
9.893 USD
Spread / Average Target
+143.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
CARDIFF ONCOLOGY, INC. Stock Cardiff Oncology, Inc.
+175.00% 182M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. CRDF Stock
  4. Financials Cardiff Oncology, Inc.